MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 -
Germany
MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 -
Germany
This page is part of the MII IG Kerndatensatz-Modul Onkologie (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions
| Offizielle URL: https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2026 | Version: 2027.0.0-ballot.1 | |||
| Active Stand: 2026-03-10 | Maschinenlesbarer Name: MII_CM_Onko_ATC_Transitions_2026 | |||
Diese ConceptMap dokumentiert die ATC-Code-Änderungen von 2025 zu 2026. c-MET-Kinase-Inhibitoren wurden in die neue Untergruppe L01EP umklassifiziert.
Language: de
Profiles: CRMI Shareable ConceptMap, CRMI Publishable ConceptMap
Mapping from MII VS Onkologie Systemische Therapie Substanzen ATC 2025 to MII VS Onkologie Systemische Therapie Substanzen ATC 2026
Mapping from http://fhir.de/CodeSystem/bfarm/atc (Atc) to http://fhir.de/CodeSystem/bfarm/atc (Atc)
| Source Code | Relationship | Target Code | Comment |
| L01EX17 (Capmatinib) | is equivalent to | L01EP01 (Capmatinib) | Reklassifizierung zu c-MET-Kinase-Inhibitoren (neue Untergruppe L01EP) |
| L01EX21 (Tepotinib) | is equivalent to | L01EP02 (Tepotinib) | Reklassifizierung zu c-MET-Kinase-Inhibitoren (neue Untergruppe L01EP) |